Gankyrin Antibody (Rabbit mAb) [K15B19]

CatNo: F3307

    Application: Reactivity:
    • Lane 1: Hela, Lane 2: Hela (KO PSMD10), Lane 3: K562, Lane 4: HepG2
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    転写条件(ウェット): 200 mA, 60 min

    使用情報

    Dilution
    1:1000 - 1:10000
    1:50 - 1:100
    1:100
    1:80
    Application
    WB, IHC, IF, FCM
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    24 kDa 24 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human lung adenocarcinoma tissue; Human infiltrating duct carcinoma of breast tissue; HeLa cells; HepG2 cells; K562 cells; 293 cells
    ネガティブコントロール

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 60 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IF
    Experimental Protocol:
     
    Sample Preparation
    1. Adherent Cells: Place a clean, sterile coverslip in a culture dish. Once the cells grow to near confluence as a monolayer, remove the coverslip for further use.
    2. Suspension Cells: Seed the cells onto a clean, sterile slide coated with poly-L-lysine.
    3. Frozen Sections: Allow the slide to thaw at room temperature. Wash it with pure water or PBS for 2 times, 3 minutes each time.
    4. Paraffin Sections: Deparaffinization and rehydration. Wash the slide with pure water or PBS for 3 times, 3 minutes each time. Then perform antigen retrieval.
     
    Fixation
    1. Fix the cell coverslips/spots or tissue sections at room temperature using a fixative such as 4% paraformaldehyde (4% PFA) for 10-15 minutes.
    2. Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Permeabilization
    1.Add a detergent such as 0.1–0.3% Triton X-100 to the sample and incubate at room temperature for 10–20 minutes.
    (Note: This step is only required for intracellular antigens. For antigens expressed on the cell membrane, this step is unnecessary.)
    Wash the sample with PBS for 3 times, 3 minutes each time.
     
    Blocking
    Add blocking solution and incubate at room temperature for at least 1 hour. (Common blocking solutions include: serum from the same source as the secondary antibody, BSA, or goat serum.)
    Note: Ensure the sample remains moist during and after the blocking step to prevent drying, which can lead to high background.
     
    Immunofluorescence Staining (Day 1)
    1. Remove the blocking solution and add the diluted primary antibody.
    2. Incubate the sample in a humidified chamber at 4°C overnight.
     
    Immunofluorescence Staining (Day 2)
    1. Remove the primary antibody and wash with PBST for 3 times, 5 minutes each time.
    2. Add the diluted fluorescent secondary antibody and incubate in the dark at 4°C for 1–2 hours.
    3. Remove the secondary antibody and wash with PBST for 3 times, 5 minutes each time.
    4. Add diluted DAPI and incubate at room temperature in the dark for 5–10 minutes.
    5. Wash with PBST for 3 times, 5 minutes each time.
     
    Mounting
    1. Mount the sample with an anti-fade mounting medium.
    2. Allow the slide to dry at room temperature overnight in the dark.
    3. Store the slide in a slide storage box at 4°C, protected from light.
     
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    Gankyrin Antibody (Rabbit mAb) [K15B19] detects endogenous levels of total Gankyrin protein.
    タンパク質の局在
    細胞質、細胞核
    Uniprot ID
    O75832
    Clone
    K15B19
    Synonym(s)
    26S proteasome non-ATPase regulatory subunit 10, 26S proteasome regulatory subunit p28, Gankyrin, p28(GANK), PSMD10
    Background
    Gankyrin, also known as PSMD10 or p28GANK, is a proteasome-associated oncoprotein belonging to the ankyrin repeat family, acting as a regulatory subunit of the 26S proteasome that integrates cell-cycle, stress-response, and oncogenic signaling through high-affinity protein–protein interactions mediated by a tandem array of ankyrin repeats. The ankyrin repeat architecture provides a modular scaffold that engages cyclin-dependent kinase 4 (CDK4), the retinoblastoma tumor suppressor (RB), and the E3 ubiquitin ligase MDM2, positioning gankyrin as a central adaptor that couples phosphorylation, ubiquitination, and proteasomal degradation of key cell-cycle and apoptotic regulators. Within the CDK4–RB axis, gankyrin binding promotes CDK4 activation and enhances RB phosphorylation, followed by accelerated recruitment of phosphorylated RB to the 26S proteasome, which diminishes RB-mediated repression of E2F transcription factors and supports sustained entry into and progression through the cell cycle in proliferating hepatocytes and tumor cells. In parallel, interaction with MDM2 increases MDM2 E3 ligase activity toward p53, augmenting p53 ubiquitination and delivery of polyubiquitylated p53 to the proteasome, thereby reducing p53-dependent transcriptional programs linked to DNA damage responses and apoptosis and favoring survival under genotoxic and oncogenic stress. Gankyrin facilitates the targeting function of the proteasome by bridging CDK4 and MDM2 with the 19S regulatory particle, which supports more efficient recognition and processing of multiple polyubiquitylated substrates and consolidates its role as a dual negative regulator of the RB and p53 tumor suppressor pathways. In hepatocellular carcinoma (HCC), gankyrin is frequently overexpressed and extends its regulatory impact to metabolic signaling by activating β-catenin/c-Myc signaling, leading to increased transcription of glucose and glutamine transporters and glycolytic and glutaminolytic enzymes, such as GLUT1 and GLS1, which collectively shift cellular metabolism toward enhanced aerobic glycolysis and glutaminolysis. This metabolic reprogramming supports anabolic growth, migration, and metastatic potential and associates high gankyrin expression with increased glucose uptake, lactate production, glutamine utilization, and glutamate synthesis in HCC cell lines and patient-derived xenografts, indicating that gankyrin coordinates proteasome-dependent degradation of tumor suppressors with c-Myc-driven metabolic adaptation. The interplay between gankyrin and β-catenin also affects transcriptional circuits beyond metabolism, as elevated β-catenin correlates with high gankyrin levels in HCC biopsies and the combined expression pattern predicts poor overall survival, consistent with its wider impact on Wnt/β-catenin target genes involved in proliferation and invasion. Overexpression of gankyrin in liver cancer cells enhances proliferation, protects against apoptosis induced by DNA-damaging agents, and promotes tumorigenicity and metastasis, outcomes that reflect simultaneous attenuation of RB and p53 signaling and reinforcement of oncogenic β-catenin/c-Myc pathways. Inhibition of gankyrin-mediated proteasomal interactions reduces CDK4 and MDM2 activity, restores RB and p53 protein levels, and increases apoptosis in cancer cells, underscoring its importance as a mechanistic hub that governs tumor suppressor stability and cellular fate decisions. At the structural-functional level, the ankyrin repeat array and proteasome-binding surfaces enable gankyrin to operate as a docking platform that coordinates substrate recognition, ubiquitin-tag transfer, and proteasome engagement, properties that are directly relevant when designing assays to monitor gankyrin activity or screening for small molecules that disrupt its interactions with CDK4, MDM2, or the 19S regulatory complex. In physiological contexts such as liver regeneration and chronic liver disease, gankyrin-driven degradation of tumor suppressor proteins contributes to hepatocyte proliferation and may facilitate the transition from compensatory growth to malignant transformation when its expression becomes chronically elevated. Dysregulation of gankyrin, particularly in HCC and other gastrointestinal malignancies, is therefore characterized by coordinated suppression of RB and p53 checkpoints and reinforcement of β-catenin/c-Myc metabolic signaling, a combination that underpins early cell-cycle deregulation, sustained anabolic metabolism, and enhanced metastatic behavior and provides multiple mechanistic entry points for therapeutic targeting.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください